Ivarmacitinib

DRUG7 trials

Conditions

Behcet's SyndromeMetastatic Breast CancerPalmoplantar Pustulosis (PPP)Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAERheumatoid ArthritisTakayasu Arteritis (TAK)Triple Negative Breast Cancer (TNBC)aGVHD

Phase 1

A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation

Not yet recruitingNCT07381114

Institute of Hematology & Blood Diseases Hospital, ChinaaGVHD

Start: 2026-02-14End: 2027-12-30Target: 32Updated: 2026-02-02

Phase 2

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Not yet recruitingNCT06731153

Fudan UniversityMetastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)

Start: 2024-12-31End: 2027-12-31Target: 40Updated: 2024-12-12

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Not yet recruitingNCT07313202

Fujian Cancer HospitalPatients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

Start: 2025-12-10End: 2028-12-26Target: 72Updated: 2025-12-31

Ivarmacitinib for Refractory Behcet's Syndrome

WithdrawnNCT07634848

Liu TianBehcet's Syndrome

Start: 2026-06-01End: 2027-05-31Updated: 2026-07-10

Phase 4

Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis

Not yet recruitingNCT07452445

Tongji HospitalRheumatoid Arthritis

Start: 2026-03-01End: 2029-03-01Target: 100Updated: 2026-03-05

Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

Not yet recruitingNCT07451665

Chinese SLE Treatment And Research GroupTakayasu Arteritis (TAK)

Start: 2026-04-01End: 2029-03-31Target: 180Updated: 2026-03-05

Unknown Phase

A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis

RecruitingNCT07270003

Xijing HospitalPalmoplantar Pustulosis (PPP)